Rothschild & Co Redburn analyst Ed Ridley-Day initiated coverage of Zimmer Biomet (ZBH) with a Buy rating and $130 price target The firm says orthopedics is one of the more mature market segments in medical technology with its growth lagging the sector. However, increasing adoption of robotic-assisted technology, penetration of the ambulatory surgery center setting in the U.S. and growth in less mature markets like shoulder, foot and ankle surgery can sustain improved market growth, the analyst tells investors in a research note. Rothschild believes Zimmer’s renewed product portfolio and increased investment should support growth acceleration and the stock’s re-rating.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet Holdings: Operational Improvements and Strategic Positioning Amid Cautious Growth Prospects
- Zimmer Biomet Holdings: Stable Performance with Limited Growth Prospects Justifies Hold Rating
- Zimmer Biomet Issues CHF 600 Million Debt Securities
- Zimmer Biomet appoints new Chief Medical Advisors
- Zimmer Biomet’s Strong Q2 Performance and Optimistic Outlook